Sandra Hoover
Nurse Practitioner · Kansas City, MONPI 1437379534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,579 and has fallen 66.2% since, to $872 in 2024. Among nurse practitioner clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$755
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$710
- Johnson & Johnson$704
- Bristol Myers Squibb$638
- Merck$389
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,58798%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $755 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $710 |
| Johnson & Johnson | 35 | $704 |
| Bristol Myers Squibb | 38 | $638 |
| Merck | 21 | $389 |
| Nestle Healthcare Nutrition Inc. | 11 | $227 |
| Pfizer | 7 | $200 |
| Fresenius Kabi USA, LLC | 9 | $183 |
| Daiichi Sankyo Inc. | 9 | $175 |
| Lilly USA, LLC | 8 | $152 |
| QOL Medical, LLC | 9 | $144 |
| Ferring Pharmaceuticals Inc. | 6 | $132 |
| Organon | 7 | $126 |
| Regeneron Healthcare Solutions, Inc. | 4 | $104 |
| Amgen | 4 | $97 |
| Sanofi | 4 | $91 |
| Ardelyx, Inc. | 5 | $82 |
| La Jolla Pharmaceutical Company | 4 | $61 |
| Braintree Laboratories, Inc. | 3 | $56 |
| Intercept Pharmaceuticals, Inc. | 3 | $50 |
| Medtronic | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Biogen | 1 | $24 |
| Mylan Institutional Inc. | 1 | $22 |
| Echosens North America, Inc. | 1 | $22 |
| Celltrion USA Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
| Exact Sciences | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,713 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 11 | $236,920 |
| ZenpepLipase/Protease/Amylase | 27 | $113,157 |
| Mesalamine | 22 | $8,579 |
| Dexlansoprazole DrDexlansoprazole | 15 | $2,540 |
| Pantoprazole Sodium | 77 | $1,187 |
| Famotidine | 64 | $1,160 |
| Colestipol Hcl | 11 | $1,022 |
| Omeprazole | 90 | $965 |
| Ondansetron OdtOndansetron | 13 | $350 |
| Neomycin Sulfate | 11 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $144 | $236,92011 claims |
| Aimmune Therapeutics, Inc.Zenpep | $13 | $113,15727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Kansas City
- Robert HafnerKansas City$47K
- Courtney JefferyKansas City$24K
- Shea FijalKansas City$18K
- Janay KissingerKansas City$14K
- Jennifer PoundKansas City$11K
- Catherine SpellKansas City$10K
- Lakeisha KellyKansas City$10K
- Moeid RiazKansas City$8K
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.